Fig. 2From: Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancerProgression-free (a) and overall (b) survival in patients treated with immunotherapy in the TMB high and TMB low cohorts, calculated from the start of immunotherapy. Progression-free (c) and overall (d) survival among patients with ES-SCLC who never received immunotherapy according to TMB status, calculated from the start date of first-line platinum/etoposide chemotherapyBack to article page